Gregory Maes

This #bloodcancerawarenessmonth we want to highlight the realities for patients in the U.K and the importance of streamlining testing. Click the link to find out how Nonacus is collaborating with a leading genomics testing hub to tackle these issues: bit.ly/3qNDCjX

Introducing a special Lunch & Learn with customer success story by Professor Tim Aitman on the use of Nonacus Custom Panels -Weds 13th Sept -1:10-3:00 PM -University of Edinburgh, Institute of Genetics and Cancer, S1.14 Room Please RSVP to [email protected]

What makes an ideal MRD marker for Acute Myeloid Leukemia? Features include: ✓ Exclusively present within the AML-defining clone ✓ Absent (or nearly absent) in the preleukemic state ✓ Correlates with therapeutic response ✓ Recurs at disease relapse bit.ly/3ONmOl2

🎉 Exciting News! Yesterday marked a significant milestone for us with the official opening of our new Birmingham HQ. We were delighted to have the distinguished presence of Angela Douglas MBE, Deputy Chief Scientific Officer for NHS England, leading the ribbon-cutting ceremony.

In our latest blog post we explore the subject of targeted NGS and explain the steps involved in a targeted NGS assay, as well as covering why targeted NGS is necessary for cell-free DNA (cfDNA) samples. bit.ly/40WPcFU

Hello from EACR Molecular Pathology. If you are attending, make sure to drop by our stand to learn about our molecular diagnostic solutions.We will also be showing a poster tomorrow (13:25 – 14:55 in the Main Hall) presented by Nonacus Senior Research Scientist Dr James Hassall.

In our latest blog post, we share five tops tips for getting the most out of the Panel Design Tool and ensuring perfect panel design every time. Click the link below to read on: bit.ly/3LmfD2X

Our marketing team is rapidly expanding and hiring for several exciting new roles. We are looking for a website manager and digital marketing specialist: to learn more about these roles click the link below: bit.ly/40rm8Gj #jobsinscience

Our team are dedicated to improving patient care: by listening to each other and our customers, clear communication and being open minded, we create solutions that will ensure we deliver on our mission. #liquidbiopsy #moleculardiagnostics #oncology #cancercare

Interested in learning more about the research behind GALEAS® Bladder? If you are attending the EAU annual meeting, our co-developer Professor Richard Bryan will be at the Nonacus booth today (A65) between 1:30 and 3pm. bit.ly/3yrxluj #EAU23

NEWS ANNOUNCEMENT- Nonacus launches GALEAS® Bladder, a novel test for the non-invasive detection of bladder cancer: Read the full press release below: bit.ly/3l0kRH7

When diagnosed at its earliest stage, more than 9 in 10 people with bladder cancer will survive their disease for one year or more. However current screening methods, via flexible cystoscopy, are expensive and require a visit to the hospital. #hematuria #bladdercancerscreening

A large proportion of #rarediseases are constitutional. That's why we have developed a range of constitutional genetics products specifically designed for detecting chromosomal abnormalities, including SNVs, indels and CNVs in a single workflow. bit.ly/3SwiCaL

Our Support Centre is home to an ever-growing collection of publications that showcase the vital work that our community is undertaking. Why not take a look? (link below) bit.ly/3IA2dif